These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 35732328)

  • 61. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
    Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
    [TBL] [Abstract][Full Text] [Related]  

  • 62. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.
    Varlet P; Le Teuff G; Le Deley MC; Giangaspero F; Haberler C; Jacques TS; Figarella-Branger D; Pietsch T; Andreiuolo F; Deroulers C; Jaspan T; Jones C; Grill J
    Neuro Oncol; 2020 Jan; 22(1):116-127. PubMed ID: 31419298
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of high-grade glioma in children and adolescents.
    MacDonald TJ; Aguilera D; Kramm CM
    Neuro Oncol; 2011 Oct; 13(10):1049-58. PubMed ID: 21784756
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluating H3F3A K27M and G34R/V somatic mutations in a cohort of pediatric brain tumors of different and rare histologies.
    Oliveira VF; De Sousa GR; Dos Santos AC; Saggioro FP; Machado HR; de Oliveira RS; Tone LG; Valera ET
    Childs Nerv Syst; 2021 Feb; 37(2):375-382. PubMed ID: 32766947
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Aberrant DNA repair reveals a vulnerability in histone H3.3-mutant brain tumors.
    Giacomini G; Piquet S; Chevallier O; Dabin J; Bai SK; Kim B; Siddaway R; Raught B; Coyaud E; Shan CM; Reid RJD; Toda T; Rothstein R; Barra V; Wilhelm T; Hamadat S; Bertin C; Crane A; Dubois F; Forne I; Imhof A; Bandopadhayay P; Beroukhim R; Naim V; Jia S; Hawkins C; Rondinelli B; Polo SE
    Nucleic Acids Res; 2024 Mar; 52(5):2372-2388. PubMed ID: 38214234
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Histone H3 K27M mutations in adult cerebellar high-grade gliomas.
    Nakata S; Nobusawa S; Yamazaki T; Osawa T; Horiguchi K; Hashiba Y; Yaoita H; Matsumura N; Ikota H; Hirato J; Yoshimoto Y; Yokoo H
    Brain Tumor Pathol; 2017 Jul; 34(3):113-119. PubMed ID: 28547652
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial.
    Rodriguez Gutierrez D; Jones C; Varlet P; Mackay A; Warren D; Warmuth-Metz M; Aliaga ES; Calmon R; Hargrave DR; Cañete A; Massimino M; Azizi AA; Le Deley MC; Saran F; Rousseau RF; Zahlmann G; Garcia J; Vassal G; Grill J; Morgan PS; Jaspan T
    Clin Cancer Res; 2020 Apr; 26(8):1856-1865. PubMed ID: 31924736
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era.
    Manoharan N; Liu KX; Mueller S; Haas-Kogan DA; Bandopadhayay P
    Neoplasia; 2023 Feb; 36():100857. PubMed ID: 36566593
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Landscape of Pediatric High-Grade Gliomas: The Virtues and Pitfalls of Pre-Clinical Models.
    Furst LM; Roussel EM; Leung RF; George AM; Best SA; Whittle JR; Firestein R; Faux MC; Eisenstat DD
    Biology (Basel); 2024 Jun; 13(6):. PubMed ID: 38927304
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pediatric-type high-grade gliomas with PDGFRA amplification in adult patients with Li-Fraumeni syndrome: clinical and molecular characterization of three cases.
    Kibe Y; Ohka F; Aoki K; Yamaguchi J; Motomura K; Ito E; Takeuchi K; Nagata Y; Ito S; Mizutani N; Shiba Y; Maeda S; Nishikawa T; Shimizu H; Saito R
    Acta Neuropathol Commun; 2024 Apr; 12(1):57. PubMed ID: 38605367
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Low-Grade Gemistocytic Morphology in H3 G34R-Mutant Gliomas and Concurrent K27M Mutation: Clinicopathologic Findings.
    Morris M; Driscoll M; Henson JW; Cobbs C; Jiang L; Gocke CD; Chen L; Rodriguez FJ
    J Neuropathol Exp Neurol; 2020 Oct; 79(10):1038-1043. PubMed ID: 32954438
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours.
    Schubert NA; Chen CY; Rodríguez A; Koster J; Dowless M; Pfister SM; Shields DJ; Stancato LF; Vassal G; Caron HN; van den Boogaard ML; Henssen AG; Molenaar JJ
    Eur J Cancer; 2022 Jul; 170():196-208. PubMed ID: 35671543
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.
    Blumenthal DT; Dvir A; Lossos A; Tzuk-Shina T; Lior T; Limon D; Yust-Katz S; Lokiec A; Ram Z; Ross JS; Ali SM; Yair R; Soussan-Gutman L; Bokstein F
    J Neurooncol; 2016 Oct; 130(1):211-219. PubMed ID: 27531351
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Modulating autophagy as a therapeutic strategy for the treatment of paediatric high-grade glioma.
    Howarth A; Madureira PA; Lockwood G; Storer LCD; Grundy R; Rahman R; Pilkington GJ; Hill R
    Brain Pathol; 2019 Nov; 29(6):707-725. PubMed ID: 31012506
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Molecular markers and targeted therapy in pediatric low-grade glioma.
    de Blank P; Fouladi M; Huse JT
    J Neurooncol; 2020 Oct; 150(1):5-15. PubMed ID: 32399739
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Radiosensitization in Pediatric High-Grade Glioma: Targets, Resistance and Developments.
    Metselaar DS; du Chatinier A; Stuiver I; Kaspers GJL; Hulleman E
    Front Oncol; 2021; 11():662209. PubMed ID: 33869066
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pediatric hemispheric high-grade glioma: targeting the future.
    Coleman C; Stoller S; Grotzer M; Stucklin AG; Nazarian J; Mueller S
    Cancer Metastasis Rev; 2020 Mar; 39(1):245-260. PubMed ID: 31989507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.